Bright Minds Biosciences Inc.

DRUG Nasdaq SEC CIK 1827401
Follow Bright Minds Biosciences Weekly email: filings, results, news

Financials

Reported figures only · latest: Q4 2024 CAD · IFRS
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income7 fiscal years
−CAD 15M−CAD 10M−CAD 5MCAD 0FY18FY19FY20FY21FY22FY23FY24
Show the numbers
YearNet income
FY24−CAD 2.8M
FY23−CAD 7.4M
FY22−CAD 15M
FY21−CAD 8.7M
FY20−CAD 480.4K
FY19-
FY18-

News

No stories filed under Bright Minds Biosciences yet - coverage appears here as the news feed clusters it.